Literature DB >> 32656519

Associated Features with Non-Sentinel Lymph Node Involvement in Early Stage Breast Cancer Patients who Have Positive Macrometastatic Sentinel Lymph Node.

Hakan Ataş1, Buket Altun Özdemir1, Ebru Menekşe1, Sabri Özden1, Yunus Nadi Yüksek1, Gül Dağlar2.   

Abstract

OBJECTIVE: The main goal of this study is to determine the clinico-pathological factors that correlate non-sentinel lymph nodes (LNs) involvement in clinically node negative breast cancer (BC) patients with positive macrometastatic sentinel lymph node (SLN) in order to derive future evidence to define a subgroup where completion axillary lymph node dissection (cALND) might not be recommended.
MATERIALS AND METHODS: Total 289 SLN biopsies were performed in clinically node negative BC patients between March 2014 and April 2017. Seventy patients who performed cALND due to positive macrometastatic SLN were retrospectively selected and classified into two groups, according to non-SLN involvement (NSLNI). Clinico-pathological features of patients were examined computerized and documentary archives.
RESULTS: Extracapsular extension (ECE) of SLN, number of harvested SLNs, metastatic rate of SLNs, absence of ductal carcinoma in situ (DCIS) and presence of multilocalization were significantly associated with the likelihood of non-SLN involvement after univariate analysis (p<0,05). Absence of DCIS and presence of multilocalization were found to be significant after multivariate analysis.
CONCLUSION: Careful examination of clinico-pathological features can help to decide avoiding cALND if enough LNs are removed and the rate of SLN metastases is low, particularly in case DCIS accompanying invasive cancer in patients without multi localized tumour.
Copyright © 2020 Turkish Federation of Breast Diseases Associations.

Entities:  

Keywords:  Breast cancer; lymphatic metastasis; sentinel lymph node biopsy

Year:  2020        PMID: 32656519      PMCID: PMC7337922          DOI: 10.5152/ejbh.2020.5332

Source DB:  PubMed          Journal:  Eur J Breast Health


  30 in total

1.  Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?

Authors:  André Hennigs; Melitta Köpke; Manuel Feißt; Fabian Riedel; Mahdi Rezai; Ulrike Nitz; Mareike Moderow; Michael Golatta; Christof Sohn; Andreas Schneeweiss; Jörg Heil
Journal:  Breast Cancer Res Treat       Date:  2018-10-12       Impact factor: 4.872

2.  Predicting four or more metastatic axillary lymph nodes in patients with sentinel node-positive breast cancer: assessment of existent risk scores.

Authors:  Benjamin Zendejas; Tanya L Hoskin; Amy C Degnim; Carol A Reynolds; David R Farley; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2010-04-29       Impact factor: 5.344

3.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

Authors:  Mila Donker; Geertjan van Tienhoven; Marieke E Straver; Philip Meijnen; Cornelis J H van de Velde; Robert E Mansel; Luigi Cataliotti; A Helen Westenberg; Jean H G Klinkenbijl; Lorenzo Orzalesi; Willem H Bouma; Huub C J van der Mijle; Grard A P Nieuwenhuijzen; Sanne C Veltkamp; Leen Slaets; Nicole J Duez; Peter W de Graaf; Thijs van Dalen; Andreas Marinelli; Herman Rijna; Marko Snoj; Nigel J Bundred; Jos W S Merkus; Yazid Belkacemi; Patrick Petignat; Dominic A X Schinagl; Corneel Coens; Carlo G M Messina; Jan Bogaerts; Emiel J T Rutgers
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

4.  Factors predicting the non-sentinel lymph node involvement in breast cancer patients with sentinel lymph node metastases.

Authors:  D E Boler; C Uras; U Ince; N Cabioglu
Journal:  Breast       Date:  2012-03-10       Impact factor: 4.380

5.  The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1-T2 breast cancer.

Authors:  Jessica Gooch; Tari A King; Anne Eaton; Lynn Dengel; Michelle Stempel; Adriana D Corben; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2014-04-29       Impact factor: 5.344

6.  A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive.

Authors:  A Pal; E Provenzano; S W Duffy; S E Pinder; A D Purushotham
Journal:  Br J Surg       Date:  2008-03       Impact factor: 6.939

7.  A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy.

Authors:  Kimberly J Van Zee; Donna-Marie E Manasseh; Jose L B Bevilacqua; Susan K Boolbol; Jane V Fey; Lee K Tan; Patrick I Borgen; Hiram S Cody; Michael W Kattan
Journal:  Ann Surg Oncol       Date:  2003-12       Impact factor: 5.344

8.  Predictors of nonsentinel node metastasis in patients with breast cancer after sentinel node metastasis.

Authors:  Kathie-Ann Joseph; Mahmoud El-Tamer; Ian Komenaka; Andrea Troxel; Beth Ann Ditkoff; Freya Schnabel
Journal:  Arch Surg       Date:  2004-06

9.  Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.

Authors:  Armando E Giuliano; Karla Ballman; Linda McCall; Peter Beitsch; Pat W Whitworth; Peter Blumencranz; A Marilyn Leitch; Sukamal Saha; Monica Morrow; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-09       Impact factor: 12.969

10.  New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients.

Authors:  Holbrook E Kohrt; Richard A Olshen; Honnie R Bermas; William H Goodson; Douglas J Wood; Solomon Henry; Robert V Rouse; Lisa Bailey; Vicki J Philben; Frederick M Dirbas; Jocelyn J Dunn; Denise L Johnson; Irene L Wapnir; Robert W Carlson; Frank E Stockdale; Nora M Hansen; Stefanie S Jeffrey
Journal:  BMC Cancer       Date:  2008-03-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.